Tirzepatide, sold as Mounjaro®, represents a major advancement in diabetes care. It is the first agent to activate both GIP and GLP-1 receptors, approved by the FDA in 2022. Compared to other drugs, tirzepatide provides stronger reductions in HbA1c and body weight while maintaining a similar safety profile. In the SURPASS-4 trial, it also demonstrated reduced mortality during the COVID-19 pandemic. These results suggest tirzepatide may hold promise not only for T2D but also for related comorbidities like obesity.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Hemi Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
